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Abstract 
Fucoidan is a generic term for a class of fucose rich, structurally diverse sulfated 
polysaccharides that are found in brown algae and other marine organisms. Depending on 
the species from which the fucoidan is extracted, a wide variety of biological activities 
including antitumor, antiinflammatory, immune-modulating, antiviral, antibacterial and pro- 
and anticoagulant activities has been described. Fucoidans have the advantage of low 
toxicity and oral bioavailibiity and are viable drug candidates, preclinical and pilot clinical 
trials show promising results. The availability of robust assays, in particular for analysing the 
blood levels of fucoidan, is a fundamental requirement for pharmacokinetic analysis in drug 
development projects. This contribution describes the application of a commercially 
availbale, protein-free fluorescent probe assay (Heparin Red) for the direct quantification of 
several fucoidans (from Fucus vesiculosus, Macrocystis pyrifera, and Undaria pinnatifida) in  
human plasma. By only minor adapation of the established protocol for heparin detection, a 
concentration range 0,5 – 20 µg/mL fucoidan can be addressed. A preliminary analysis of 
matrix effects suggests acceptable interindividual variability and no interference by 
endogeneous chondroitin sulfate. This study identifies the Heparin Red assay as a simple, 
time-saving mix-and-read method for the quantification of fucoidans in human plasma.  
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Introduction 
Fucoidans are structurally diverse, fucose-rich sulfated polysaccharides that are commonly 
extracted from brown algae. A major structural motif are repeating, sulfated fucose units, 
linked by  α-1,3 or α-1,4 bonds (scheme 1). [1] In contrast to glycosaminoglycans, most 
fucoidans are highly branched.  
Fucoidans are a natural bioactive ingredients of marine functional foods. Depending on the 
species from which they have been extracted, fucoidans exhibit a broad spectrum of 
biological activities, including antitumor, anti-inflammatory, immuno-modulating, antiviral, 
antibacterial, anticoagulant and procoagulant effects [2-14]  
 
Scheme 1. α-1,3-linked, sulfated fucose unit, as present in many fucoidans. Sulfation pattern is 
variable, fucose may be monosulfated, disulfated or non-sulfated.    
 
Currently, there are no approved uses for fucoidan in medical applications. It is, however, 
considered a promising drug candidate due to lack of toxicity, good biocompatibility, oral 
bioavailability, and encouraging results in preclinical and sporadic early-stage clinical trials.    
For drug development and approval, pharmacokinetic analysis needs to be considered.  A 
fundamental requirement for understanding the pharmacokinetics of fucoidan is the 
availability of robust analytical methods, in particular for determining the blood levels of the 
target compound.  
A limited number of assays for the detection of fucoidan in plasma or serum samples has 
been reported. A competitive ELISA was developed in 2005  and applied to the quantification 
of  an Undaria pinnatifida fucoidan in plasma after oral ingestion of the compound by human 
volunteers. Plasma levels in the range 4 - 13 µg/mL have been reported. [15] Later, a more 
sensitive (low ng/mL range) sandwich Elisa was described for Cladosiphon okanuramus 
fucoidan in human serum and urine; no cross reactivity to heparin was observed.[16,17] Both 
ELISAs require sample pretreatment (boiling and centrifugation), and several washing steps 
and overall incubation times of several hours are necessary. A polyion-sensitive membrane 
electrode for the direct, potentiometric detection of fucoidan in buffer in the range 0,5 – 50 
µg/mL was recently described; fucoidan could also be indirectly measured in fetal bovine 
serum (2,5 – 7,5 µg/mL), using a modified method that includes protamine titration of the 
fucoidan and detection of free protamine by a protamine-sensitive membrane electrode.[18] 
To our knowledge, none of these approaches has been translated in a generally available 
commercial assay.  
 
Besides these assays for plasma and serum levels of fucoidan, a size exclusion 
chromatography HPLC method with UV detection at 210 nm was applied to fucoidan 
detection in buffer, as well as in urine at concentrations in the range about 5-250 µg/mL. [19]  
A filter paper spot test using methylene blue staining allows the colorimetric detection of 
fucoidan in buffer and bovine serum albumin solutions; the method requires an analyte 
quantity of about 1 µg [20].  Very recently, a sensitive fluorescence assay was reported for 
fucoidan detection in aqueous extracts, using the nucleic acid stain SYBR gold [21], and a 
modified toluidine blue assay specific for sulfated polysaccharides, including fucoidan, in the 
presence of carboxylated polysaccharides. [22]  
We describe here the quantification of Fucoidan in spiked human plasma samples by the 
commercially available Heparin Red Kit. The latter is a fluorescent probe assay that has 
been developed for the direct detection of heparin in plasma samples.[23, 24] Heparins 
display certain structural similarities to fucoidans with respect to their polymeric 
(polysaccharide) nature  and high negative charge density due to sulfation. The 615 nm 
fluorescence emission of Heparin Red lies at the edge of the “optical transparency window” 
of blood at longer wavelengths, so that interference by colored components and 
autofluorescence is minimised. The molecular probe is a polyamine-functionalized perylene 
diimide that forms a supramolecular complex with the polyanionic polysaccharide target. 
Aggregation of the probe molecules at the polysaccharide template results in contact 
quenching of fluorescence (scheme 2). Since this response mechanism is independent of 
any anticoagulant activity, the Heparin Red assay is also capable of detecting non-
anticoagulant heparins [25] and is emerging [26] as a valuable tool for pharmacokinetic 
studies of this promising class of drug candidates since the standard heparin assays based 
on interaction with coagulation factors are not applicable.  
 
Scheme 2. Schematic representation of fluorescence quenching of the molecular probe Heparin Red 
in the presence of polyanionic polysaccharides.     
 
Here we describe for the first time the application of the Heparin Red Kit to the detection of 
several fucoidans in spiked human plasma samples, by implementing only a minor 
modification of the routine protocol for heparin detection.  
 
 
 
Materials and Methods 
Instrumentation 
Fluorescence measurements 
Fluorescence was measured with a microplate reader Biotek Synergy Mx (Biotek  
Instruments, Winooski, VT, USA), excitation at 570 nm, emission recorded at 605 nm,  
spectral band width 13,5 nm, read height of 8 mm. 
 
Microplates 
For fluorescence measurements 96 well microplates, polystyrene,  Item No 655076, were 
purchased from Greiner Bio-One GmbH, Frickenhausen.  
 
Pipettes  
Transferpette® 100-1000µl, Transferpette® 10-100µl, Transferpette®-8 20-200µl, purchased 
from Brand GmbH, Wertheim. Rainin Pipettes 100-1000µl, 20-200µl, and 2-20µl purchased 
from Mettler Toledo, OH, USA. 
 
Data analysis 
Data were analyzed using Excel (Microsoft Office 10) and OriginPro 8.1. First order 
exponential decay was applied to Heparin Red calibration curves with F. vesiculosus 
fucoidan.  Fucoidan concentrations of the single-donor plasmas shown in table 3 are given 
relative to calibration curves for the respective analyte in spiked pooled normal plasma.  
 
 
Reagents 
 
Kits 
The Heparin Red® Kit  was a gift from Redprobes UG, Münster, Germany. Kit components: 
Heparin Red solution, Product No HR001, Lot 01-003, and Enhancer Solution, Product No 
ES001, Lot 004. 
Fucoidans 
Fucoidans were purchased from Sigma-Aldrich GmbH, Steinheim: Fucoidan from Fucus 
vesiculosus, purity >95%, product number F8190, Lot SLBN8754V.   Fucoidan from 
Macrocystis pyrifera, purity > 85%, product number F8065, Lot SLBP2754V. Fucoidan from 
Undaria pinnatifida, purity > 95%, product number F8315, Lot SLBQ0431V.  
 
 
 
Plasma 
Pooled normal plasma (Lot A1161, Cryocheck, Precision Biologic, NS, Kanada) consists of a 
pool of normal citrated human plasma from a minimum of 20 healthy donors. Storage 
conditions of the pooled normal plasma prior to spiking with fucoidans was -80°C. The 
fucoidan spiked plasma samples were stored at -20°C. 
Five single-donor citrated plasmas of healthy individuals were provided by the Blood Bank of 
the Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg (IKTZ). The single 
donor plasmas were applied as matrix for the detections of table 3. The fucoidan spiked 
single donor plasmas were stored at -20°C. 
   . 
Other 
Aqueous solutions were prepared with HPLC grade water purchased from VWR, product No 
23595.328. Chondroitinsulfate A sodium salt from bovine trachea, product number C9819, 
Lot SLBQ0017V, 85% pure according to 13C NMR spectrum (Certificate of analysis), and 
Chondroitinase ABC from Proteus vulgaris, lyophilized powder, product number C3667, were 
received from Sigma-Aldrich GmbH, Steinheim.   
 
 
Assays 
 
Heparin Red® Kit 
For determination of fucoidan concentrations in plasma samples, the protocol of the provider 
for a 96-well microplate assay was followed, with minor adaptations in order to address 
different concentration ranges of fucoidan.  Mixtures of Heparin Red solution and Enhancer 
solution were freshly prepared as follows: 
Enhancer solution Heparin Red solution Fucoidan concentration range sensitivity 
9 mL 100 µL 2-20 µg/mL low 
9 mL 50 µL 1-10 µg/mL medium 
9 mL 25 µL 0,5-5 µg/mL high 
  
20 µL of the fucoidan spiked plasma sample was pipetted into a microplate well, followed by 
80 µL of the Heparin Red – Enhancer mixture. The microplate was introduced in the 
fluorescence reader and mixing was performed using the plate shaking function of the 
microplate reader (setting “high”, 3 minutes). Immediately after mixing, fluorescence was 
recorded within 1 minute. 
 
     
 
Spiked plasma samples 
Plasma samples containing defined mass concentrations of fucoidans were prepared by 
adding aqueous solutions (10 vol%) of the corresponding fucoidan to plasma and vortexing, 
to achieve a concentration of 100 µg/mL. Fucoidan concentrations required for the detections 
were adjusted by further dilution of this 100 µg/mL stock solution with the same plasma and 
vortexing. The spiked plasma samples were stored at -20°C for at least one day and up to 2 
months, thawed at room temperature and vortexed before use. Similarly, a chondroitinsulfate  
plasma spike of concentration 48 µg/mL was prepared.  
 
Chondroitin sulfate assay 
For determination of chondroitin sulfate in plasma samples with the Heparin Red Kit, the 
protocol of the provider for a 96-well microplate assay was followed with minor adaptations, 
using a mixture of 9 mL Enhancer solution and 100 µL Heparin Red solution. Chondroitin 
sulfate spiked plasma samples were used instead of heparin spiked plasma samples.  
Sample pre-treatment with chondroitinase ABC was performed at 0,27 U/mL enzyme 
concentration in the plasma sample for 20 minutes. 
 
 
Results and discussion 
Detection of fucoidans in the concentration range 1-10 µg/mL 
The Heparin Red fluorescence assay was applied to three commercially available fucoidans, 
extracted from different seaweed species: Fucus vesiculosus, Macrocystis pyrifera, and 
Undaria pinnatifida . Literature data for selected structural features of these types of fucoidan 
are given in table 1. 
Fucoidan  MW (kDa) Fucose % Uronic acid % Sulfation ratio 
F. vesiculosus 82,5 43,1 8,7 0,81 
M. pyriferia 176,4 30,5 12,7 1,1 
U. pinnatifida 51,7 32,6 4,0 0,85 
Table 1. Structural properties of the fucoidan types used in this study, as reported in [9]. MW refers to 
the peak average molar weight as determined by gel permeation chromatography. % refers to 
absolute mass per cent. Sulfation ratio is the average number of sulfate groups per monosaccharide 
moiety (note that fucoidans also contain other monosaccharides such as galactose, not included in the 
present table).  
Data in table 1 indicate a similar sulfation degree between 0,81 and 1,1 for the three fucoidan 
types. The sulfation degree is of particular relevance in this context since it determines the 
negative charge density, and electrostatic interactions contribute significantly to the strong 
 
binding of the polycationic molecular probe Heparin Red [23, 24]. An additional, although 
minor contribution to negative charge density of fucoidans may arise from negatively charged 
carboxylate groups of uronic acids.   
The response of the Heparin Red assay to fucoidan plasma spikes in the concentration 
range 1-10 µg/mL is shown in figure 1. Since Heparin Red is expected to form non-
fluorescent aggregates with fucoidan, the fluorescence intensity dereases with increasing 
plasma levels of the analyte. Response to the different fuciodans is similar, slightly weaker 
for the M. pyrifera compound. In view of the limited purity of the commercial fucoidan 
preparations (95% for F. vesiculosus and U. pinnatifida, 85% for M. pyrifera), these subtle 
differences in response behaviour will not be discussed here with respect to the different 
charge densities of the fucoidans (table 1). The results in Fig. 1 suggest  that the Heparin 
Red assay is suitable for the direct detection of various fucoidans in human plasma in the 
concentration range about 1-10 µg/mL.  
 
Figure 1. Normalized dose response curves of the Heparin Red fluorescence assay in the presence of 
various fucoidans (F. vesiculosus, M. pyriferia, U. pinnatifida). Spiked pooled normal plasma samples. 
Manually performed microplate assay, using a mixture of 50 µL Heparin red and 9 mL Enahncer 
solution. Excitation at 570 nm, fluorescence emission at 605 nm. Averages of duplicate 
determinations; CVs (averaged over all concentrations) between 1,9 (M. pyrifera) and 6,5 % (F. 
vesiculosus and U. pinnatifida), depending on the fucoidan type. 
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Tuning the sensitivity of the Heparin Red assay for fucoidan 
For a selected fucoidan (Fucus vesiculosus), we have extended the sensitive range by 
variation of the fluorescent probe concentration in the detection solution (see Materials and 
Methods for details).  Half concentration of the probe results in a stronger relative 
fluorescence quenching at lower fucoidan plasma levels, and a sensitive range of about 0,5 – 
5 µg/mL can be addressed. At double concentration of the probe, the detection range is 
shifted to higher concentrations, about 2-20 µg/mL. (Figure 2).   
 
Figure 2. Normalized dose response curves of the Heparin Red fluorescence assay in the presence of 
F. vesiculosus fucoidan. Sensitivity of the Heparin red assay (low, medium, high) is tuned by the 
concentration of the fluorescent probe in the detection solution (see Materials and Methods for 
details). Spiked pooled normal plasma samples. Manually performed microplate assay Excitation at 
570 nm, fluorescence emission at 605 nm. Averages of triplicate determinations; CVs (averaged over 
all concentrations) between 2,0 and 7,9 %, depending on sensitivity level (low: 7,9%; medium 2,0 %; 
high: 3,2%). 
The detection medium for low sensitivity (blue diamonds in Fig. 2) corresponds to that of the 
standard protocol for heparin detection. Compared with unfractionated heparin [23], a higher 
mass concentration of fucoidan is required to trigger 50% fluorescence quenching. This is 
interpreted with the higher charge density of heparin, -1,7 vs about -0,81 considered for F. 
vesiculosus fucoidan (sulfation degree, table 1), and the tendency of Heparin Red to form 
charge neutral aggregates with the polyanionic target.[24]   
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Standard deviations (n=8) for selected fucoidan concentrations 8, 4 and 2 µg/mL that yield 
about 50% fluorescence quenching for assay sensitivities low, medium and high, 
respectively, are given in table 2. In this evaluation, intraassay-variability is somewhat higher 
for the highest sensitivity level.   
 Low: c = 8 µg/mL  Medium: c = 4 µg/mL High: c = 2 µg/mL 
F/F0 average 0,46 0,52 0,60 
F/F0 range 0,41 - 0,49 0,49 - 0,58 0,51 - 0,68 
SD 0,03 0,03 0,05  
Table 2. Intraassay variability (n=8) of F. vesiculosus fucoidan detection by the Heparin Red assay at 
the different sensitivity levels (low, medium, high, compare figure 2).  
 
Plasma matrix effects 
Interference of fucoidan determination in plasma by heparin is obvious, in particular since 
heparin triggers stronger response of Heparin Red than fucoidan does. For a subgroup of 
people under heparin therapy, the Heparin Red kit may therefore not provide accurate results 
in plasma fucoidan determination. 
We have also addressed the question of a potential interference by endogeneous 
glycosaminoglycans (GAGs). Chondroitin sulfate (CS) is considered the main 
glycosaminoglycan in human plasma, and several studies report an average CS mass 
concentrations  of about 5 µg/mL in normal human plasma [27-29]  Also, several studies 
describe that most of the plasma CS is an undersulfated form, with sulfation degrees 
between 25% and 54% per disaccharide, what corresponds to a charge density of – 0,62 to -
0,77 per monosaccharide moiety. [27, 29, 30] This is lower than the charge density of the 
investigated fucoidans.  
We have also tested potential CS interference experimentally by pre-treating the pooled 
normal plasma used in this study with chondroitinase ABC. This enzyme cleaves CS into 
shorter oligosaccharide chains and ultimately disaccharides that are not detected by Heparin 
Red. If any interfering  chondroitin sulfate is present in the plasma sample, enzymatic pre-
treatment should result in a higher fluorescence of Heparin Red relative to untreated plasma 
since the oligosaccharide chains that trigger fluorescence quenching have been eliminated. 
We see, however, no difference in fluorescence intensity between the chondroitase pre-
treated and control sample after incubation with Heparin Red (Fig. 3, left). As a control 
experiment, the plasma was spiked with 48 µg/mL CS from bovine lung. The sample without 
enzymatic pre-treatment displays a significantly lower fluorescence, indicating a weak 
 
response of Heparin Red to this CS (Fig. 3, right). The chondroitinase treated sample, on the 
other hand, has a fluorescence comparable to that of a CS free sample, indicating effective 
depolymerization of CS to short saccharides that do not trigger a response of Heparin Red. 
We conclude that there is no significant interference by chondroitin sulfate in normal plasma 
of healthy individuals. In this context, it would be interesting to apply the Heparin Red Kit for 
monitoring the potential activity of fucoidanases [31] in human plasma, in order to verify 
detection of fucoidans if the presence of interfering glycosaminoglycans  such as heparin is 
suspected.  
 
Figure 3. Fluorescence response of the Heparin Red fluorescence assay to unspiked pooled normal 
plasma without (blue bars) or with (red bars) pre-treatment by chondroitinase (0,27 U/mL), and to 
chondroitin sulfate (48 µg/mL) spiked pooled normal plasma without (blue bars) or with (red bars) pre-
treatment by chondroitinase.  Manually performed microplate assay. Excitation at 570 nm, 
fluorescence emission at 605 nm. Averages of duplicate determinations.  
The interindividual variability of the fucoidan determination by Heparin Red was explored 
using F. vesiculosus fucoidan spiked plasma samples of five healthy donors.  Fucoidan 
concentrations were assigned by comparison with a calibration curve (corresponding to the 
red curve in figure 3) with spiked pooled normal plasma.  Interindividual variation (table 3) is 
within an acceptable range, although higher than the intraassay variability for repeated 
measurements of the same plasma sample (table 2), indicating a substantial  influence of the 
plasma matrix on assay results.  
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Spike conc. 
µg/mL 
0,0 1,0 2,0 4,0 6,0 8,0 
Average (µg/mL) -0,1 0,9 1,8 4,3 6,5 8,1 
Range (µg/mL) -0,3 - 0,2 0,7 - 1,2 1,6 - 2,1 3,8 - 4,8 5,6 - 7,1 7,8 – 8,6 
SD (µg/mL) 0,19 0,18 0,17 0,38 0,58 0,30 
Table 3.  Determination of F. vesiculosus fucoidan concentrations (µg/mL) by the Heparin Red assay  
in spiked plasmas of healthy donors (n=5). Concentrations were determined relative to a  calibration 
curve with spiked pooled normal plasma. Averages of duplicate determinations. 
Conclusion 
This study describes the application of a direct fluorescence assay (Heparin Red) for the 
quantification of fucoidans in human plasma. Although the assay has been optimized for 
heparin detection, it can be applied to fucoidans with only minor adapations of the routine 
protocol to achieve sensitive detection in the range 0,5 - 20 µg/mL with <10% intraassay 
variability. In comparison with other literature described analysis methods, we see a major 
strength of this microplate assay in the simple, time-saving mix-and-read protocol (less than 
10 minutes for measuring 16 samples in duplicate, calibration included). In contrast, ELISAs 
[15-17] for specific fucoidans require plasma or serum sample pre-treatment, and several 
washing and incubation steps, resulting in overall assay times of several hours. Analysis time 
of a potentiometric membrane method for fucoidan detection in a bovine serum sample [18] 
is also significantly higher since based on a protamine titration with multiple additions. A 
limitation of the Heparin Red assay is its lower sensitivity when compared with one ELISA 
[16] (low ng/mL range), and the cross-reactivity with the anticoagulant drug heparin. Heparin 
interference may [15] or may not [16] be present with ELISAs, and has not been addressed 
for the potentiomtric membrane method. Regarding endogeneous glycosaminoglycans, we 
have shown that interference of fucoidan detection with Heparin Red by chondroitin sulfate, 
the major plasma glycosaminoglycan, is unlikely in normal plasma.  Fucoidan concentrations 
in spiked plasmas of healthy donors (n=5) were determined relative to a calibration curve 
with pooled normal plasma, with acceptable variability between individuals.  
We see great potential of the Heparin Red assay for pharmacokinetic and clinical studies in 
fucoidan related drug development projects and treatment studies of diseases. Also, the 
subject of oral bioavailability of fucoidans still requires considerably more understanding [9], 
and the assay seems suitable for the screening of fucoidan plasma levels after oral ingestion 
of fucoidans or fucoidan-rich marine functional foods. In addition,  
 
 
Conflict of interest. R.K. holds shares in Redprobes UG, Münster, Germany. Other authors: 
No conflict of interest.  
 
References  
[1] Chevolot L, Mulloy B, Ratiskol J, Foucault A, Colliec-Jouaultb S. A disaccharide repeat 
unit is the major structure in fucoidans from two species of brown algae. Carbohydrate 
Research 2001; 330:529–535. 
[2] Berteau O, Mulloy B. Sulfated fucans, fresh perspectives: structures, functions, and 
biological properties of sulfated fucans and an overview of enzymes active toward this class 
of polysaccharide. Glycobiology 2003; 13:29R-40R. 
[3] Cumashi A, Ushakova N A, Preobrazhenskaya M E, D'Incecco A, Piccoli A, Totani L, 
Tinari N, Morozevich G E, Berman A E, Bilan M I. A comparative study of the anti-
inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different 
fucoidans from brown seaweeds. Glycobiology 2007; 17:541-552. 
[4] Li B, Lu F, Wei X, Zhao R. Fucoidan: structure and bioactivity. Molecules 2008; 13:1671-
1695. 
[5] Ale M T, Mikkelsen J D, Meyer A S. Important Determinants for Fucoidan Bioactivity: A 
Critical Review of Structure-Function Relations and Extraction Methods for Fucose-
Containing Sulfated Polysaccharides from Brown Seaweeds.  Mar Drugs 2011; 9:2106-2130. 
[6] Morya V K, Kim J, Kim E K. Algal fucoidan: structural and size-dependent bioactivities 
and their perspectives. Appl Microbiol Biotechnol 2012; 93:71–82.  
[7] Kwak J Y. Fucoidan as a marine anticancer agent in preclinical development. Mar Drugs 
2014; 12:851–870.   
[8] Ustyuzhanina N E, Ushakova N A, Preobrazhenskaya M E, Bilan M I, Tsvetkova E A, 
Krylov V B, Anisimova N A, Kiselevskiy M V, Krukovskaya N V, Li C, Yu G, Saran S, Saxena 
R K, Usov A I, Nifantiev N E. Fucoidans as a platform for new anticoagulant drugs discovery. 
Pure Appl Chem. 2014; 86:1365–1375.  
[9] Fitton J H, Stringer D N,  Karpiniec S S. Therapies from Fucoidan: an Update. Mar. Drugs 
2015; 13:5920-5946.  
[10] Thuy T T T, Ly B M, Van T T T, Van Quang N, Tu H C, Zheng Y, Seguin-Devaux C, Mi 
B, Usov A I. Anti-HIV activity of fucoidans from three brown seaweed species. Carbohydrate 
Polymers. 2015; 115:122-128.  
[11] Atashrazm F, Lowenthal R M, Woods G M, Holloway A F, Dickinson J L. Fucoidan and 
Cancer: A Multifunctional Molecule with Anti-Tumor Potential.  Mar. Drugs 2015; 13: 2327-
2346.  
 
[12] Zhanga Z, Tillc S, Knappec S, Quinna C, Catarelloa J, Raya G J, Scheiflingerc F, 
Szaboa C M, Dockal M. Screening of complex fucoidans from four brown algae species as 
procoagulant agents. Carbohydrate Polymers. 2015; 115:677–685.  
[13] Schneider T, Ehrig K, Liewert I, Alban S. Interference with the CXCL12/CXCR4 axis as 
potential antitumor strategy: superiority of a sulfated galactofucan from the brown alga 
Saccharina latissima and fucoidan over heparins.  Glycobiology 2015; 25:812-24. 
[14] Zaporozhets T, Besednova N. Prospects for the therapeutic application of sulfated 
polysaccharides of brown algae in diseases of the cardiovascular system: review. Pharm 
Biol. 2016; DOI:10.1080/13880209.2016.1185444 
[15] Irhimeh M R, Fitton J H, Lowenthal R M, Kongtawelert P. A quantitative method to detect 
fucoidan in human plasma using a novel antibody. Methods Find Exp Clin Pharmacol. 2005; 
27:705–710. 
[16] Tokita Y, Nakajima K, Mochida H, Iha M, Nagamine T. Development of a fucoidan-
specific antibody and measurement of fucoidan in serum and urine by sandwich elisa. Biosci. 
Biotechnol Biochem. 2010; 74:350–357.  
[17] Nagamine T, Nakazato K, Tomioka S, Iha M, Nakajima K. Intestinal absorption of 
fucoidan extracted from the brown seaweed, cladosiphon okamuranus. Mar Drugs. 2015; 13: 
48–64. 
[18] Kim J M, Nguyen L, Barr M F, Morabito M, Stringer D, Fitton J H, Mowery K A. 
Quantitative determination of fucoidan using polyion-sensitive membrane electrodes. Anal 
Chim Acta 2015; 877:1–8. 
[19] Nagamine T, Hayakawa K, Nakazato K, Iho M. Determination of the active transport of 
fucoidan derived from okinawa mozuku across the human intestinal caco-2 cells as assessed 
by size-exclusion chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2015; 
997:187-193. 
[20] Lee J M, Shin Z U, Mavlonov G T, Abdurakhmonov I Y, Yi T H. Solid-phase colorimetric 
method for the quantification of fucoidan. Appl Biochem Biotechnol. 2012; 168:1019–1024. 
[21] Yamazaki Y, Nakamura Y, Nakamura T. A fluorometric assay for quantification of 
fucoidan, a sulfated polysaccharide from brown algae. Plant Biotechnology 2016; 33: 117-
121. 
[22] Hahn T, Schulz M, Stadtmüller R, Zayed A, Muffler K, Lang S, Ulber R. Cationic Dye for 
the Specific Determination of Sulfated Polysaccharides.  Anal Lett. 2016; 49:1948-1962. 
[23] Szelke H, Schuebel S,  Harenberg J, Kraemer, R.  A fluorescent probe for the 
quantification of heparin in clinical samples with minimal matrix interference. Chem 
Commun. 2010;46: 1667-1669. 
 
[24] Szelke H, Harenberg J, Schübel S, Krämer R. Interaction of heparin with cationic 
molecular probes: probe charge is a major determinant of binding stoichiometry and affinity. 
Bioorg Med Chem Lett. 2010;20: 1445-1447. 
[25] Cassinelli G, Naggi A. Old and new applications of non-anticoagulant heparin. Int J 
Cardiol. 2016;21251: S14-S21.  
[26] Galli M, Magen H, Einsele H, Chatterjee M, Grasso M, Specchia G,  Barbieri P, Paoletti 
D, Pace S, Sanderson R D, Rambaldi A, Nagle A. Roneparstat (SST0001), an innovative 
heparanase (HPSE) inhibitor for multiple myeloma (MM) therapy: first in man study. Blood 
2015, 126, 3246-3246. 
[27] Volpi N, Maccari F. Microdetermination of chondroitin sulfate in normal human plasma 
by fluorophore-assisted carbohydrate electrophoresis (FACE). Clin Chim Acta 2005; 
356:125-133.  
[28] Volpi N, Maccari F. Chondroitin sulfate in normal human plasma is modified depending 
on the age. Its evaluation in patients with pseudoxanthoma elasticum. Clin Chim Acta 2006;  
370:196-200.  
[29] Zinellu E, Lepedda A J, Cigliano A, Pisanu S, Zinellu A, Carru C, Bacciu P P, Piredda F, 
Guarino A, Spirito R, Formato M. Association between Human Plasma Chondroitin Sulfate 
Isomers and Carotid Atherosclerotic Plaques. Biochem Res Int. 2012; 2012:Article ID 
281284. 
[30] Juvani M, Friman C, Ranta H, Wegelius O. Isolation and characterization of 
undersulfated chondroitin-4- sulfate from normal human plasma. Biochim Biophys Acta 1975; 
411: 1-10. 
[31] Kusaykin M I, Silchenko A S, Zakharenko A M, Zvyagintseva T N. Fucoidanases. 
Glycobiology 2016; 26:3-12. 
 
 
 
 
 
 
 
 
 
 
 
